Medivir, Novartis Resolve Dispute Over Partially Overlapping Patents

Law360, New York (August 13, 2004, 12:00 AM EDT) -- Swedish specialized pharmaceutical company Medivir and Swiss drug maker Novartis have resolved a dispute over partially overlapping patents in the U.S. for antiviral combination products, the two companies said.

The two companies penned a two-way license agreement to settle the case, they said. Under the agreement, Medivir will have exclusive rights to topical combination products containing the antiviral agent acyclovir or omaciclovir, Medivir's antiviral substance.

In turn, Novartis is granted a non-exclusive licence to certain antiviral combination products such as penciclovir, while Medivir will retain the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.